{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.3","upperLimit":"100","value":"85.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Overall survival is defined as the percentage of participants alive from time of diagnosis up to 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive panobinostat nanoparticle formulation MTX110 IT by CED infusion on day 1 or days 1 and 2 as determined by dose level. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.\n\nPanobinostat Nanoparticle Formulation MTX110: Given IT\n\nConvection-Enhanced Delivery (CED): Undergo CED","id":"OG000","title":"Phase 1: Treatment (MTX110)"}],"paramType":"NUMBER","populationDescription":"While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study","reportingStatus":"POSTED","timeFrame":"Up to 12 Months","title":"Overall Survival Rate (OS) at 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}